求助PDF
{"title":"GBA1 基因突变和 APOE 多态性对阿什肯纳兹犹太人路易体痴呆症患者的存活率和病情发展的影响","authors":"Tamara Shiner, Gitit Kavé, Anat Mirelman, Keren Regev, Yoav Piura, Orly Goldstein, Mali Gana Weisz, Anat Bar‐Shira, Tanya Gurevich, Avi Orr‐Urtreger, Roy N. Alcalay, Nir Giladi, Noa Bregman","doi":"10.1002/mds.30003","DOIUrl":null,"url":null,"abstract":"BackgroundGlucocerebrosidase 1 <jats:italic>(GBA1)</jats:italic> mutations are associated with reduced survival in Parkinson's disease but their effect on survival in dementia with Lewy bodies (DLB) is unclear.ObjectiveTo assess the impact of <jats:italic>GBA1</jats:italic> mutations on survival among Ashkenazi Jews with DLB, while controlling for <jats:italic>APOE</jats:italic> status.MethodsOne hundred and forty participants from Tel Aviv Medical Center, Israel were genotyped for <jats:italic>GBA1</jats:italic> mutations and <jats:italic>APOE</jats:italic> polymorphisms. Survival rates and follow‐up cognitive screening scores were analyzed.Results<jats:italic>GBA1</jats:italic> mutation carriers had a two‐fold increased risk of death (HR = 1.999), while <jats:italic>APOE</jats:italic> status did not independently affect survival. In a subset of patients with available clinical data (N = 63), carriers of the <jats:italic>APOE ε4</jats:italic> allele showed faster cognitive deterioration, while <jats:italic>GBA1</jats:italic> mutation carriers also declined more rapidly albeit not significantly.ConclusionUnderstanding the genetic effects on survival and progression is crucial for patient counseling and inclusion in clinical trials. © 2024 The Author(s). <jats:italic>Movement Disorders</jats:italic> published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"381 1","pages":""},"PeriodicalIF":7.4000,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of GBA1 Mutations and APOE Polymorphisms on Survival and Progression Among Ashkenazi Jews with Dementia with Lewy Bodies\",\"authors\":\"Tamara Shiner, Gitit Kavé, Anat Mirelman, Keren Regev, Yoav Piura, Orly Goldstein, Mali Gana Weisz, Anat Bar‐Shira, Tanya Gurevich, Avi Orr‐Urtreger, Roy N. Alcalay, Nir Giladi, Noa Bregman\",\"doi\":\"10.1002/mds.30003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BackgroundGlucocerebrosidase 1 <jats:italic>(GBA1)</jats:italic> mutations are associated with reduced survival in Parkinson's disease but their effect on survival in dementia with Lewy bodies (DLB) is unclear.ObjectiveTo assess the impact of <jats:italic>GBA1</jats:italic> mutations on survival among Ashkenazi Jews with DLB, while controlling for <jats:italic>APOE</jats:italic> status.MethodsOne hundred and forty participants from Tel Aviv Medical Center, Israel were genotyped for <jats:italic>GBA1</jats:italic> mutations and <jats:italic>APOE</jats:italic> polymorphisms. Survival rates and follow‐up cognitive screening scores were analyzed.Results<jats:italic>GBA1</jats:italic> mutation carriers had a two‐fold increased risk of death (HR = 1.999), while <jats:italic>APOE</jats:italic> status did not independently affect survival. In a subset of patients with available clinical data (N = 63), carriers of the <jats:italic>APOE ε4</jats:italic> allele showed faster cognitive deterioration, while <jats:italic>GBA1</jats:italic> mutation carriers also declined more rapidly albeit not significantly.ConclusionUnderstanding the genetic effects on survival and progression is crucial for patient counseling and inclusion in clinical trials. © 2024 The Author(s). <jats:italic>Movement Disorders</jats:italic> published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.\",\"PeriodicalId\":213,\"journal\":{\"name\":\"Movement Disorders\",\"volume\":\"381 1\",\"pages\":\"\"},\"PeriodicalIF\":7.4000,\"publicationDate\":\"2024-08-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Movement Disorders\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/mds.30003\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Movement Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/mds.30003","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
引用
批量引用